Project: Improved Treatment OF Morning Akinesia with new delayed release levodopa products.

Developing a treatment for morning akinesia in Parkinson’s disease (explained in section 2), to solve a serious unmet need for many patients. This will be done by developing a new levodopa formulation that has a profile of delivering the active drug as a delayed but rapid release in the lover part of the small intestine. For this, we will develop formulation technology, which has a build in delay in the release of its active ingredient for 4-5 hours after the tablet dose is taken.

Acronym	ITOFMA (Reference Number: 9238)
Duration	01/05/2015 - 01/07/2017
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 2

Project partner

Number	Name	Role	Country
20011	Solural Pharma ApS	Coordinator	Denmark
20012	Contera Pharma ApS	Partner	Denmark
20013	Erweka GmbH	Partner	Germany
20014	Ernst Moritz Arndt University of Greifswald	Partner	Germany